CSL Limited: Valuation Has Broken, But the Business Hasn't — Yet

CSL Limited: Valuation Has Broken, But the Business Hasn't — Yet

CSL Limited has lost two-thirds of its market value since mid-2024, collapsing from AUD 308 to the AUD 108 level after a sequence of earnings misses, guidance downgrades, and a staggering $7.1 billion in impairments booked in fiscal year 2026. The company reported its full-year results on August 17, and the headline numbers were brutal on paper. Underlying revenue fell 1% to $15.8 billion. Underlying net profit after tax dropped 13% to $2.8 billion. On a GAAP basis, CSL posted a $2.6 billion net loss.

But the market's reflexive selling has pushed the multiple into a zone where the cash flow story and the dividend story start to do more work than the impairment accounting. CSL generated $3.5 billion from operations in FY2026, maintained its $2.92-per-share dividend, and just announced a further A$1.1 billion share buyback. Forward earnings power, stripped of non-cash write-downs, trades at roughly 12 times EV/EBITDA.

The question is not whether CSL's operating problems are real. They are. The question is whether the multiple has already priced in enough bad news to make the risk/reward asymmetrical. I think it has — with one important caveat that the company needs to earn over the next two quarters.

What Actually Happened in FY2026

CSL calls FY2026 a "reset year." That is a fair description. The company is working through the worst of a Vifor acquisition hangover, a drug-pricing reform shock in U.S. immunoglobulin, and flu vaccine weakness in the United States. The transformation program announced in May 2026 has already delivered $176 million in cost savings, exceeding initial targets.

On the impairment front, CSL booked $7.1 billion in one-off write-downs — primarily against Vifor intangible assets — plus $800 million in restructuring costs. These are accounting charges, not cash outflows. They destroy GAAP earnings but do not drain the bank account. The underlying NPATA metric (net profit after tax excluding impairments and restructuring) came in at $3.1 billion, down just 2% from the prior year.

Breaking it down by segment tells the real story. CSL Behring, the core plasma-derived therapeutics business, delivered $11.4 billion in revenue, down 1%. The immunoglobulin franchise — built on Privigen and Hizentra — was hammered by U.S. Medicare Part D reforms that management estimates cost roughly 100 basis points of margin. But trailing six-month like-for-like immunoglobulin growth actually turned positive at 3%, and management expects double-digit growth in the back half of FY2027. Albumin in China took a hit from government policy enforcement, though over 100 new hospital listings and a retail partnership with Beheil Medical suggest a path back.

Newer products are showing promise. HEMGENIX, the gene therapy for hemophilia B, grew 16%. ANDEMBRY, launched for hereditary angioedema less than a year ago, already has more than 1,000 patients on therapy. These are not scale businesses yet, but they represent a shift away from the older plasma franchise toward higher-margin specialty therapies.

CSL Vifor is the problem child. The nephrology and iron therapy unit is facing approximately 25% revenue decline, driven by generic competition in iron products and the conclusion of the TDAPA framework (a terminated drug access and pricing agreement that kept Velphoro prices artificially elevated). The $7.1 billion in impairments is the accounting system's way of admitting that the $11.7 billion paid for Vifor in 2022 was too much. That is a sunk cost. The forward question is whether Vifor can stabilize at a lower revenue base and still contribute margin.

Seqirus, the influenza vaccine business, declined roughly 2% in FY2026 but outperformed a global flu market that management projected would be down mid-to-high single digits. The U.S. immunization rate problem remains structural and has been harder to reverse than anticipated. Still, the differentiation advantage of cell-based and adjuvant vaccines (Flucelvax and Fluad) keeps Seqirus competitive within a shrinking market.

Cash Flow Is Doing the Heavy Lifting

This is where the stock becomes interesting. CSL generated $3.5 billion in operating cash flow in FY2026, despite the revenue decline, the margin pressure, and the capital investment cycle. Free cash flow stands at AUD 4.14 billion on a trailing twelve-month basis.

That cash flow supports a dividend of $2.92 per share, or roughly 2.5% yield at current prices. CSL completed a $1 billion share buyback in FY2026 and has announced another A$1.1 billion buyback program. The company also plans $1.5 billion in investment in U.S. plasma manufacturing, which is the long-term growth engine for Behring.

The balance sheet is the one area that warrants caution. Total debt sits at AUD 15.75 billion against AUD 2.19 billion in cash, for a net debt position of roughly AUD 13.6 billion. That is manageable for a company generating this level of cash flow, but it is not low. The debt burden was taken on to fund the Vifor acquisition, and the company now has to service it while the acquired business is shrinking.

Valuation Has Reset — But How Far?

CSL now trades at approximately 14.7 times forward earnings, based on forward P/E estimates. Enterprise value sits at AUD 79.5 billion, or roughly 12 times EV/EBITDA. The trailing P/E is meaningless — a fractional figure distorted by the $7.1 billion in impairments — but the forward multiple tells the real story.

Thirteen times forward earnings and 12 times EV/EBITDA for a company that generates $3.5 billion in operating cash flow, pays a maintained dividend, and operates in plasma therapeutics (a structurally undersupplied market) is not expensive. It is not screaming bargain either, because the forward growth trajectory is thin.

CSL's FY2027 guidance calls for flat revenue at constant currency and roughly 5% underlying NPAT growth. That is not the high single-digit organic growth the market used to expect from CSL three years ago. The transformation program, cost savings, and Behring recovery are supposed to drive that 5%, with Vifor pulling the other way.

Still, 5% earnings growth on a 12-times EBITDA multiple is the kind of setup where modest execution upside compounds into meaningful re-rating. If Behring immunoglobulin returns to double-digit growth in H2 FY2027 as management expects, and if cost savings accelerate beyond the current $176 million run rate, the NPAT growth could run above 5%. And the multiple would have room to drift back toward 15 or 16 times EBITDA as the market stops pricing in further Vifor carnage.

The Catalyst Clock

There are two near-term proof points that will determine whether this thesis holds.

First, H1 FY2027 earnings, expected in February 2027. Investors will want to see Behring immunoglobulin growth returning to double digits on a sequential basis, Vifor decline stabilizing rather than accelerating, and cost savings running at a meaningful pace. If Behring delivers double-digit IG growth while Vifor decline stays near the 25% range management has flagged, the operating trajectory will be clear.

Second, the $1.5 billion U.S. plasma manufacturing investment. CSL has committed to expanding domestic plasma collection and manufacturing capacity, which is the long-term margin engine. The plasma supply constraint is a structural tailwind that has persisted across the industry. Execution on this investment — capacity timelines, collection site expansion, and the VarmX strategic collaboration announced this year — will matter for multi-year revenue visibility.

Risks That Could Break the Thesis

I am not asking investors to ignore the problems. The risks are real and they are interconnected.

Vifor's decline trajectory is the most visible one. A 25% revenue drop in FY2026, with further generic erosion expected in FY2027 when Injectafer loses exclusivity in the U.S., means the decline could be larger than $170 million in lost annual sales. If Vifor costs more to restructure than management's $550 million annual savings target, the bottom-line drag compounds.

Behring's margin recovery is conditional on U.S. hospital field force expansion and the Medicare Part D headwind fading. If the Part D reforms prove more structural than temporary, the 100 basis point margin hit could become a permanent drag. Albumin in China is similarly contingent on regulatory cooperation — the government has demonstrated willingness to crush pricing when it chooses to.

Seqirus faces a structural problem in the U.S. flu vaccine market. Immunization rates have softened and management has already walked back medium-term growth guidance from double digits to high single digits. There is no near-term catalyst that reverses this trend, and flu vaccine is now more of a cash-flow maintenance business than a growth engine.

Finally, the debt load. AUD 15.75 billion in gross debt on a company whose revenue is declining and whose acquired business is being impaired is not a crisis today, but it limits flexibility. If the transformation program stalls or Behring growth disappoints, the balance sheet becomes a constraint.

The Call

CSL Limited is a Buy for investors who can tolerate a broken business in the process of being repaired. The stock has been sold into a forward multiple that prices in further carnage beyond what the operating trajectory warrants. The $3.5 billion in operating cash flow, the maintained dividend, the buyback program, and the 12-times EV/EBITDA multiple together form a floor that is lower than most investors realize.

This is not a turnaround call based on a new growth narrative. It is a valuation reset call. The market sold CSL because the Vifor acquisition fell apart, because Behring took a reform hit, and because Seqirus is structurally weaker. Those are all true. But the multiple has fallen faster than the cash flow has deteriorated, and the forward earnings path — flat revenue with 5% NPAT growth — is already reflected in the price.

What would make me downgrade from this position? A Behring miss in H1 FY2027 that shows immunoglobulin growth has stalled, Vifor decline accelerating beyond the 25% range, or a transformation program that fails to hit the $550 million savings target. Until those things happen, the risk/reward at this multiple still favors the buyer.